A Study to Collect Information of People With Narcolepsy in Spain
Launched by TAKEDA · Dec 9, 2020
Trial Information
Current as of April 25, 2025
Completed
Keywords
ClinConnect Summary
This is a non-interventional, cross-sectional study with retrospective medical chart review conducted in public and private Spanish sleep clinics, to describe the management of adult participants diagnosed with narcolepsy defined by ICDS-3 in real world practice.
This study will enroll approximately 196 participants (137 with NT1 and 59 with NT2). Participants will be enrolled in 2 cohorts:
* Cohort A: NT1 Participants
* Cohort B: NT2 Participants
The data will be collected retrospectively through clinical records and at study visit (clinical and demographic data, and participant related...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. With confirmed diagnosis of narcolepsy defined by ICDS-3.
- • 2. With at least 1-year follow-up with data available at the participating site after initial narcolepsy diagnosis and before study inclusion.
- • 3. With data available at the participant site at least 1-year before first narcolepsy diagnosis.
- • 4. Capable to fulfill the study questionnaires.
- Exclusion Criteria:
- • 1. Participating in a clinical trial (less than or equal to \[\<=\] 12 months).
- • 2. With any serious degenerative disease (Alzheimer, Parkinson or epilepsy) or psychiatric condition.
Trial Officials
Study Director
Study Director
Takeda
About Takeda
Takeda Pharmaceutical Company Limited is a global, research-driven biopharmaceutical organization committed to advancing patient care through innovative therapies. Founded in 1781 and headquartered in Osaka, Japan, Takeda focuses on key therapeutic areas including oncology, gastroenterology, neuroscience, and rare diseases. With a strong emphasis on research and development, Takeda leverages cutting-edge science and technology to deliver transformative medicines that address unmet medical needs. The company is dedicated to sustainability and ethical practices, ensuring that its clinical trials uphold the highest standards of safety and efficacy while fostering collaboration with healthcare professionals and communities worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Barcelona, Cataluna, Spain
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials